Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease

• Published in: Journal of rheumatology Vol. 40; no. 5; p. 640
• Main Authors: Fischer, Aryeh, Brown, Kevin K, Du Bois, Roland M, Frankel, Stephen K, Cosgrove, Gregory P, Fernandez-Perez, Evans R, Huie, Tristan J, Krishnamoorthy, Mahalakshmi, Meehan, Richard T, Olson, Amy L, Solomon, Joshua J, Swigris, Jeffrey J
• Format: Journal Article
• Language: English
• Published: Canada 01.05.2013
• Subjects: Connective Tissue Diseases - complications; Connective Tissue Diseases - diagnosis; Connective Tissue Diseases - drug therapy; Connective Tissue Diseases - physiopathology; Female; Humans; Immunosuppressive Agents - adverse effects; Immunosuppressive Agents - therapeutic use; Longitudinal Studies; Lung - drug effects; Lung - physiopathology; Lung Diseases, Interstitial - diagnosis; Lung Diseases, Interstitial - drug therapy; Lung Diseases, Interstitial - etiology; Lung Diseases, Interstitial - physiopathology; Male; Middle Aged; Mycophenolic Acid - adverse effects; Mycophenolic Acid - analogs & derivatives; Mycophenolic Acid - therapeutic use; Patient Dropouts; Respiratory Function Tests; CONNECTIVE TISSUE DISEASE; INTERSTITIAL LUNG DISEASE; MYCOPHENOLATE MOFETIL

Small series suggest mycophenolate mofetil (MMF) is well tolerated and may be an effective therapy for connective tissue disease-associated interstitial lung disease (CTD-ILD). We examined the tolerability and longitudinal changes in pulmonary physiology in a large and diverse cohort of patients wit...